Prediction of Liver-related Outcomes After HCV Cure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1035 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: To develop and validate a predictive model, applicable to daily practice, of liver complications emergence in hepatitis C virus (HCV)-infected patients and advanced fibrosis, who have achieved sustained viral response (SVR) with direct-acting antivirals (DAA)-based therapy.

Methods:

Design: Mulsite prospective multicenter cohort study. Study subjects: HCV-monoinfected and HIV/HCV-coinfected individuals recruited from two parallel cohorts (GEHEP-MONO Cohort clinicaltrials.gov ID: NCT02333292(HEPAVIR-DAA Cohort clinicaltrials.gov ID: NCT02057003). These cohorts enrolled patients with HCV infection, treated with DAA-based regimens after October 2011, at the units of infectious diseases of 18 hospitals throughout Spain. Patients who fullfilled the following inclusion criteria are included in this study: 1) Have received a regimen with one or more DAA; 2) Have achieved SVR 12 weeks after treatment; 3) Have an evaluable liver stiffness (LS) of more than 9.5 kPa in the three months prior to the start of treatment.

Follow-up: The baseline time point is the date of SVR. All participants are evaluated by a common protocol every six months. At every visit, clinical and laboratory examination focusing on the early detection of liver complications are carried out. LS is assessed by vibration-controlled transient elastography, according to a standardized procedure, every 12 months. In patients with cirrhosis, liver ultrasound and plasma alpha-fetoprotein determination are conducted for hepatocellular carcinoma screening, every six months.

Variables and data analysis: The primary outcome variable of the study will be the emergence of liver complication (hepatic decompensation or hepatocellular carcinoma) or liver transplant. Predictive models will be develop with clinical, analytical, and genetic variables independently associated with the primary variable in a Cox regression for competitive risks applied to a developmental subpopulation. The performance of the model will be evaluated using COR curves. Sensitivity, specificity, and positive and negative predictive values will be calculated, both in the developmental population and in a validation population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals

NCT05062408

Hepatitis C, Chronic

COMPLETED

Long Term Follow-up of Hepatitis C Cured Patients

NCT03246048

Chronic Hepatitis C Chronic Liver Disease Cirrhosis

COMPLETED

Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents.

NCT02802280

Hepatitis C Cardiovascular Diseases

UNKNOWN PHASE4

Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients

NCT02057003

Hepatitis C, Chronic Human Immunodeficiency Virus

UNKNOWN

Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis

NCT00301509

Liver Cirrhosis, Experimental

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C, Chronic Sustained Virological Response Direct-acting Antivirals Hepatocellular Carcinoma Hepatic Decompensation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Had achieved SVR 12 weeks after DAA-based regimen, either with or without Peg-interferon
* Showed liver stiffness (LS) value ≥9.5 kPa prior to treatment
* Had LS measurement available at SVR time-point